Your browser is no longer supported. Please, upgrade your browser.
TEVA Teva Pharmaceutical Industries Limited daily Stock Chart
Teva Pharmaceutical Industries Limited
Index- P/E- EPS (ttm)-16.84 Insider Own2.70% Shs Outstand1.03B Perf Week-4.18%
Market Cap23.85B Forward P/E8.18 EPS next Y2.83 Insider Trans2.69% Shs Float977.12M Perf Month-2.65%
Income-17111.00M PEG- EPS next Q0.64 Inst Own67.30% Short Float4.54% Perf Quarter29.65%
Sales21.82B P/S1.09 EPS this Y-33.20% Inst Trans0.04% Short Ratio3.88 Perf Half Y8.03%
Book/sh14.68 P/B1.58 EPS next Y5.49% ROA-20.60% Target Price20.13 Perf Year-27.33%
Cash/sh1.38 P/C16.82 EPS next 5Y-7.82% ROE-82.20% 52W Range10.85 - 33.24 Perf YTD22.06%
Dividend0.85 P/FCF7.62 EPS past 5Y-57.50% ROI-36.00% 52W High-29.20% Beta0.73
Dividend %3.67% Quick Ratio0.60 Sales past 5Y2.00% Gross Margin47.50% 52W Low116.91% ATR0.65
Employees51800 Current Ratio1.00 Sales Q/Q-10.40% Oper. Margin-77.70% RSI (14)50.47 Volatility1.96% 2.69%
OptionableYes Debt/Eq2.06 EPS Q/Q81.40% Profit Margin-73.60% Rel Volume0.63 Prev Close23.13
ShortableYes LT Debt/Eq1.97 EarningsAug 02 BMO Payout- Avg Volume11.44M Price23.53
Recom3.00 SMA20-1.73% SMA504.58% SMA20026.39% Volume6,975,337 Change1.75%
Jun-27-18Reiterated Citigroup Buy $25 → $27
Mar-20-18Resumed Jefferies Hold $19
Feb-12-18Upgrade Credit Suisse Neutral → Outperform
Feb-09-18Upgrade RBC Capital Mkts Underperform → Sector Perform
Feb-09-18Downgrade Piper Jaffray Neutral → Underweight
Feb-09-18Downgrade Gabelli & Co Buy → Hold
Feb-02-18Downgrade BTIG Research Neutral → Sell $17
Jan-26-18Reiterated Leerink Partners Underperform $15 → $17
Jan-25-18Reiterated Susquehanna Positive $22 → $24
Jan-18-18Downgrade BTIG Research Buy → Neutral
Jan-09-18Upgrade Mizuho Neutral → Buy $23
Jan-05-18Downgrade Wells Fargo Market Perform → Underperform
Jan-04-18Upgrade Citigroup Neutral → Buy
Jan-03-18Initiated Leerink Partners Underperform $15
Dec-15-17Upgrade Morgan Stanley Underweight → Equal-Weight
Dec-15-17Upgrade Goldman Neutral → Buy
Dec-15-17Upgrade Credit Suisse Underperform → Neutral
Dec-12-17Initiated Guggenheim Neutral $16
Nov-29-17Reiterated Mizuho Neutral $12 → $16
Nov-17-17Reiterated Mizuho Neutral $15 → $12
Jul-17-18 08:37AM  Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4 Benzinga
08:30AM  Teva Highlights Key Milestones Achieved in the 2017 Social Impact Report Business Wire
Jul-16-18 03:24PM  Blood Pressure Medication That May Contain Cancer-Causing Impurity Is Recalled Fortune
Jul-15-18 04:51PM  Here's How Teva Pharmaceuticals Pulled Off a 28.3% Gain in the First Half of 2018 Motley Fool
Jul-13-18 08:24PM  3 Warren Buffett Stocks Worth Buying Now Motley Fool
05:58PM  FDA recalls heart drugs made by Teva, others over carcinogen impurity MarketWatch
08:49AM  4 Warren Buffett Stocks to Buy in Q2 Earnings Zacks
Jul-11-18 09:30AM  Has Teva Pharmaceutical Industries (TEVA) Outpaced Other Medical Stocks This Year? Zacks
08:00AM  Teva to Report Second Quarter 2018 Financial Results on August 2, 2018 Business Wire
Jul-09-18 12:19PM  Correction: Teva-US-HQ Move story Associated Press
10:47AM  Teva Announces Launch of a Generic Version of Uceris® in the United States Business Wire
09:30AM  TEVA or AKRX: Which Is the Better Value Stock Right Now? Zacks
08:58AM  Up in the air: Teva's 1M square feet of space in the suburbs American City Business Journals
07:25AM  Complimentary Technical Snapshots on Teva Pharma Industries and Three More Drug Makers Stocks ACCESSWIRE
Jul-06-18 05:15PM  Pharma firm Teva moving HQ to New Jersey from Pennsylvania Associated Press
02:33PM  Teva's decision to move North American HQ leaves other sites in jeopardy American City Business Journals
10:56AM  5 Pharmaceutical and Biotech Stocks to Consider for July InvestorPlace
Jul-05-18 01:52PM  Teva moving North America headquarters from North Wales to North Jersey American City Business Journals
Jun-29-18 08:10AM  Todays Research Reports on Stocks to Watch: Teva Pharmaceuticals and Gemphire Therapeutics ACCESSWIRE
Jun-28-18 08:00AM  Teva to Present New Fremanezumab Data, Including Long-Term Data, at the American Headache Societys 60th Annual Scientific Meeting Business Wire
Jun-27-18 01:13PM  Medial Devices & Teva. Plus, the bullish bet on this food... CNBC Videos
11:25AM  Stocks - ConAgra, Pinnacle Foods Tumble in Pre-Market, WWE Surges
Jun-26-18 06:31AM  3 Best Big Pharma Stocks of 2018 So Far Motley Fool
Jun-21-18 12:12PM  Mylan Stock Looks Cheap, but Dont Overlook These Risks InvestorPlace
Jun-19-18 01:25PM  CVS will offer home delivery of prescriptions Yahoo Finance Video
Jun-18-18 10:08AM  Teva to Discontinue a Fremanezumab Study on Cluster Headache Zacks
Jun-15-18 05:01PM  Teva Scraps A Study In Cluster Headaches And This Rival Benefits Investor's Business Daily
04:45PM  Here's Why Alder Biopharmaceuticals Is Rising Today Motley Fool
09:32AM  Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play InvestorPlace
08:38AM  Teva to discontinue study for chronic headache treatment Reuters
08:11AM  Teva discontinues study for chronic headache treatment Reuters
08:08AM  Teva to end late-stage trial of chronic cluster headache treatment after disappointing results MarketWatch
08:00AM  Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache Business Wire
Jun-11-18 08:20AM  Today's Research Reports on Trending Tickers: Teva Pharmaceutical and Horizon Pharma ACCESSWIRE
07:38AM  The Cheapest Drug Stocks to Buy Right Now Motley Fool
07:00AM  Should You Buy Teva Pharmaceutical Industries Limited (NYSE:TEVA) At $23.11? Simply Wall St.
Jun-07-18 07:50AM  Analysis: Positioning to Benefit within Teva Pharmaceutical Industries, Resonant, United Community Financial, Enbridge, Shopify, and Dell Technologies Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-05-18 12:00PM  Teva Releases Survey Highlighting Needs of Caregivers in Canada FSCWire
Jun-01-18 10:24AM  Nektar (NKTR) Seeks Approval for Analgesic Opioid Candidate Zacks
May-31-18 06:46PM  FDA Moves to Make Life Easier for Generic Drug Companies
02:14PM  Pfizer Inc. Stock Desperately Needs a Viagra-Like Boost InvestorPlace
12:52PM  Corcept Therapeutics Is 'Fairly Valued,' Stifel Says In Downgrade Benzinga
May-30-18 09:17AM  5 Best-Selling Orphan Drugs in the U.S. Motley Fool
08:10AM  Add Bucks County to list of those suing opioid manufacturers, distributors American City Business Journals
May-29-18 08:41AM  Teva (TEVA) Stock Up 17% YTD After a Dismal 2017: Here's Why Zacks
May-26-18 10:33AM  5 Top Stock Trades for Tuesday Morning InvestorPlace
May-25-18 09:19AM  Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended Benzinga
May-24-18 03:33PM  FDA Confirms September Action Date for Teva's Migraine Drug Zacks
09:28AM  3 Big Pharma Stocks with Huge Future Growth Potential InvestorPlace
08:30AM  Research Report Identifies Brady, RA PHARMCTL INC, Sigma Designs, Teva Pharmaceutical Industries, Bridge, and BOK Financial with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
07:33AM  Jim Cramer Gives His Opinion On Blue Apron, Teva And More Benzinga
May-23-18 07:02PM  Cramer's lightning round: I don't have a thesis for Blue ... CNBC Videos
06:48PM  Cramer's lightning round: I don't have a thesis for Blue Apron, so don't buy CNBC
10:48AM  Should You Hold Momenta (MNTA) Stock in Your Portfolio? Zacks
10:11AM  Teva hopes to launch migraine drug as soon as September Reuters
08:34AM  Teva Pharm says FDA to decide on migraine drug on Sept 16 Reuters
08:00AM  Teva Confirms September PDUFA Date for Fremanezumab Business Wire
May-22-18 11:56PM  Warren Buffett Loves TEVA Stock and You Should Too InvestorPlace
May-19-18 04:10PM  Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching Benzinga
May-18-18 05:10PM  CORRECTING and REPLACING Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association Business Wire
02:35PM  Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug Zacks
09:56AM  Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up Zacks
07:25AM  Free Stock Performance Review on Teva Pharma and Three Other Healthcare Sector ACCESSWIRE
06:08AM  Buffett Gets Even Greedier With Teva Pharmaceuticals. Time to Buy? Motley Fool
06:00AM  13F: Buffett Increased Apple, Monsanto & Teva Investopedia
May-17-18 10:23AM  Company News For May 17, 2018 Zacks
09:46AM  The Top Stocks Warren Buffett Is Buying Now Motley Fool
May-16-18 03:19PM  Warren Buffett Pushing More Cash To Equities; 'Big 5' Stocks Still At The Top Benzinga
01:32PM  Berkshire doubles Teva stake, adds to Apple, ends a newspaper bet Reuters
12:08PM  Teva Pharmaceutical Industries Ltd, Once a Falling Machete, Is Spiking Chase It InvestorPlace
11:50AM  Berkshire doubles Teva stake, adds to Apple, ends a newspaper bet Reuters
11:47AM  Corrected: Berkshire doubles Teva stake, adds to Apple, ends a newspaper bet Reuters
09:56AM  Eli Lilly's Cluster Headache Candidate Succeeds in Phase III Zacks
09:38AM  Stocks Inch Up, Dow Jones Lags; Boot Barn Spikes Out Of Buy Range Investor's Business Daily
09:34AM  Teva Shares Jump After Warren Buffett Doubles Stake in Drugmaker
09:07AM  Teva Stock Up 5% as Buffett's Berkshire Raises Stake in Q1 Zacks
07:25AM  Buffett Buys More Apple and Teva Shares, Dumps IBM Investopedia
06:00AM  Here's What Warren Buffett Is Buying and Selling Motley Fool
May-15-18 05:52PM  Buffett's company doubles investment in drugmaker Teva Associated Press
05:50PM  After-hours buzz: TEVA, MON, MU & more CNBC
05:43PM  Berkshire doubles Teva stake, adds to Apple, ends a newspaper bet Reuters
05:35PM  Teva shares up 5% on Berkshire's increased stake MarketWatch
04:46PM  Buffett's Berkshire adds to stakes in Teva and Monsanto in the first quarter CNBC
04:38PM  Berkshire Hathaway doubles Teva bet, confirms Apple purchases Reuters
04:34PM  Berkshire Hathaway doubles Teva bet, confirms Apple purchases Reuters
02:28PM  Nektar Therapeutics Stock Is Risky But Offers Big Reward InvestorPlace
11:05AM  Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association Business Wire
08:00AM  Todays Research Reports on Stocks to Watch: Precipio and Teva Pharmaceutical ACCESSWIRE
May-14-18 04:55PM  Teva Pharma Spiked To Perrigo's Detriment On Asthma Inhaler Delay Investor's Business Daily +5.54%
11:00AM  EGLT: Partnerships and Formulary Adds Impressive; Waiting for Revenue Catch Up Zacks Small Cap Research
May-13-18 09:52AM  Insider Buys Of The Week: ADS, Tesla, Teva And More Benzinga
May-11-18 05:07PM  Perrigo Drops After Saying FDA to Reject Inhaler, Delaying Start Bloomberg
05:02PM  [$$] FDA Rejects Perrigo's ProAir Generic, Drug Maker Says The Wall Street Journal
May-08-18 02:11PM  Warren Buffett's 10 Big Stock Losers Investopedia
May-07-18 04:32PM  Why Teva Pharmaceutical Industries, Gramercy Property Trust, and Medtronic Jumped Today Motley Fool
08:17AM  Teva (TEVA) Stock Dips Despite Q1 Earnings & Sales Beat Zacks
May-05-18 11:03AM  Will Teva Stock Break Down From Key Support? Investopedia
May-04-18 08:30AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Teva Pharmaceutical Industries ACCESSWIRE
May-03-18 08:35PM  Teva Shows Progress on Restructuring But Investors Want More
04:42PM  Teva Pulls Off Quarterly Beat Despite Generic Copaxone Worries Investor's Business Daily
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MIGNONE ROBERTODirectorMay 10Buy19.32250,0004,829,7001,500,000May 11 04:15 PM
MIGNONE ROBERTODirectorMay 09Buy19.21500,0009,603,1501,250,000May 11 04:15 PM
Stark David MatthewExec. VP Chief Legal OfficerMar 19Sale18.382,35843,3402,974Mar 20 04:16 PM
O'Grady Brendan P.EVP, North America CommercialMar 19Sale17.881,17921,0781,388Mar 20 04:13 PM
Nazzi GianfrancoEVP, Growth Markets CommercialMar 19Sale17.894578,1775,746Mar 20 04:11 PM
McClellan Michael JamesEVP, Chief Financial OfficerMar 19Sale17.882875,13111,295Mar 20 04:10 PM
Griffin Deborah AChief Accounting OfficerMar 19Sale17.8894316,8590Mar 20 04:08 PM
Fridriksdottir HafrunExecutive VP, Global R&DMar 19Sale17.883486,2227,051Mar 20 04:07 PM
Dethlefs SvenEVP Global Marketing&PortfolioMar 19Sale17.8857110,2084,445Mar 20 04:06 PM
Daniell RichardExec. VP, European CommercialMar 19Sale17.891,29723,2060Mar 20 04:04 PM
Stark David MatthewExec. VP Chief Legal OfficerMar 12Sale19.202,44146,8672,974Mar 14 04:35 PM
O'Grady Brendan P.EVP, North America CommercialMar 12Sale19.4973814,3831,388Mar 14 04:34 PM
Nazzi GianfrancoEVP, Growth Markets CommercialMar 12Sale19.504618,9895,331Mar 14 04:31 PM
Griffin Deborah AChief Accounting OfficerMar 12Sale19.4995218,5540Mar 14 04:29 PM
Dethlefs SvenEVP Global Marketing&PortfolioMar 12Sale19.4957611,2263,837Mar 14 04:26 PM
Daniell RichardExec. VP, European CommercialMar 12Sale19.5071413,9220Mar 14 04:23 PM
O'Grady Brendan P.EVP, North America CommercialMar 05Sale19.3870513,6631,388Mar 06 04:20 PM
Griffin Deborah AChief Accounting OfficerMar 05Sale19.3877314,9810Mar 06 04:14 PM
Daniell RichardExec. VP, European CommercialMar 05Sale19.281,10821,3620Mar 06 04:08 PM
Sabag MarkEVP, Global Human ResourcesFeb 15Sale20.523,00061,56041,517Feb 20 08:31 AM
Sabag MarkEVP, Global Human ResourcesFeb 14Sale18.452,05037,82344,517Feb 20 08:31 AM